Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ascentawits Pharmaceuticals Ltd. is managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units and involve 5 distinct examiners. This broad distribution indicates that the company's portfolio covers a variety of specialized topics within the biotech sector. The busiest examiner, HAVLIN, ROBERT H, is responsible for 1 pending action, which shows that the workload is spread evenly across the assigned staff.
The use of 4 distinct art units for 5 pending office actions suggests a degree of technical diversity in the company's filings. Because 5 distinct examiners are involved, each of the 5 pending office actions is being evaluated by a different individual. This lack of examiner overlap means that the company must develop 5 separate prosecution strategies to address the unique concerns of each official.
Practitioners should be prepared for a complex management task, as the relationship of pending actions to examiners for the busiest official, HAVLIN, ROBERT H, confirms no consolidation. The company's presence in 4 different art units within the Biotechnology & Pharmaceuticals area requires a deep understanding of various examination guidelines. Each of the 5 pending office actions represents a distinct path toward potential allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (60%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| SAWYER, JENNIFER C | 1 | 68.6% | -8.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | — |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | — |
| 18706685 | AKR1C3-ACTIVATED DNA ALKYLATING AGENT, AND MEDICAL APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | — |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | — |
| 18706685 | AKR1C3-ACTIVATED DNA ALKYLATING AGENT, AND MEDICAL APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1627 | 1 |
| 1678 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | — | §101§102§112DP | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | 1681 | §101§103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18706685 | AKR1C3-ACTIVATED DNA ALKYLATING AGENT, AND MEDICAL APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §101§102§103§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | 1678 | §103§112 | Final Rejection | — | Pending | Mar 01, 2023 |
| 18003402 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | SAWYER, JENNIFER C | 1691 | §112 | Final Rejection | 29d | Pending | Dec 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial